TY - JOUR AU - Hortobagyi, G. N. PY - 2005 DA - 2005// TI - Trastuzumab in the treatment of breast cancer JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMe058196 DO - 10.1056/NEJMe058196 ID - Hortobagyi2005 ER - TY - JOUR AU - Piccart-Gebhart, M. J. AU - Procter, M. AU - Leyland-Jones, B. PY - 2005 DA - 2005// TI - Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa052306 DO - 10.1056/NEJMoa052306 ID - Piccart-Gebhart2005 ER - TY - JOUR AU - Romond, E. H. AU - Perez, E. A. AU - Bryant, J. PY - 2005 DA - 2005// TI - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa052122 DO - 10.1056/NEJMoa052122 ID - Romond2005 ER - TY - JOUR AU - Slamon, D. AU - Eiermann, W. AU - Robert, N. PY - 2011 DA - 2011// TI - Adjuvant trastuzumab in HER2-positive breast cancer JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa0910383 DO - 10.1056/NEJMoa0910383 ID - Slamon2011 ER - TY - JOUR AU - Cameron, D. AU - Piccart-Gebhart, M. J. AU - Gelber, R. D. PY - 2017 DA - 2017// TI - 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial JO - Lancet VL - 389 UR - https://doi.org/10.1016/S0140-6736(16)32616-2 DO - 10.1016/S0140-6736(16)32616-2 ID - Cameron2017 ER - TY - JOUR AU - Pivot, X. AU - Romieu, G. AU - Debled, M. PY - 2013 DA - 2013// TI - 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70225-0 DO - 10.1016/S1470-2045(13)70225-0 ID - Pivot2013 ER - TY - JOUR AU - Mavroudis, D. AU - Saloustros, E. AU - Malamos, N. PY - 2015 DA - 2015// TI - Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic oncology research group (HORG) JO - Ann Oncol VL - 26 ID - Mavroudis2015 ER - TY - STD TI - Conte PF, Bisagni G, Frassoldati A et al. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: results of the phase III multicentric Italian study short-HER. J Clin Oncol 2017; 35: 501–501. ID - ref8 ER - TY - JOUR AU - Tan-Chiu, E. AU - Yothers, G. AU - Romond, E. PY - 2005 DA - 2005// TI - Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.02.4091 DO - 10.1200/JCO.2005.02.4091 ID - Tan-Chiu2005 ER - TY - JOUR AU - Suter, T. M. AU - Procter, M. AU - van Veldhuisen, D. J. PY - 2007 DA - 2007// TI - Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.1611 DO - 10.1200/JCO.2006.09.1611 ID - Suter2007 ER - TY - JOUR AU - Procter, M. AU - Suter, T. M. AU - de Azambuja, E. PY - 2010 DA - 2010// TI - Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin adjuvant (HERA) trial JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.0463 DO - 10.1200/JCO.2009.26.0463 ID - Procter2010 ER - TY - JOUR AU - de Azambuja, E. AU - Procter, M. J. AU - van Veldhuisen, D. J. PY - 2014 DA - 2014// TI - Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin adjuvant trial (BIG 1-01) JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.53.9288 DO - 10.1200/JCO.2013.53.9288 ID - de Azambuja2014 ER - TY - JOUR AU - Perez, E. A. AU - Suman, V. J. AU - Davidson, N. E. PY - 2008 DA - 2008// TI - Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central Cancer treatment group N9831 adjuvant breast cancer trial JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.5467 DO - 10.1200/JCO.2007.13.5467 ID - Perez2008 ER - TY - JOUR AU - Russell, S. D. AU - Blackwell, K. L. AU - Lawrence, J. PY - 2010 DA - 2010// TI - Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and bowel project B-31 and the north central Cancer treatment group N9831 clinical trials JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.23.6950 DO - 10.1200/JCO.2009.23.6950 ID - Russell2010 ER - TY - JOUR AU - Pivot, X. AU - Suter, T. AU - Nabholtz, J. M. PY - 2015 DA - 2015// TI - Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.05.028 DO - 10.1016/j.ejca.2015.05.028 ID - Pivot2015 ER - TY - JOUR AU - Earl, H. M. AU - Vallier, A. L. AU - Dunn, J. PY - 2016 DA - 2016// TI - Trastuzumab-associated cardiac events in the Persephone trial JO - Br J Cancer VL - 115 UR - https://doi.org/10.1038/bjc.2016.357 DO - 10.1038/bjc.2016.357 ID - Earl2016 ER - TY - STD TI - Hiller L, Loi S, Vallier AL, et al. Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. In: NCRI Cancer conference. Liverpool; 2017. ID - ref17 ER -